Twist Bioscience (NASDAQ:TWST) Reaches New 12-Month High – What’s Next?

Twist Bioscience Corporation (NASDAQ:TWST) hit a new 52-week high on Tuesday. The company traded as high as $187.87 and last traded at $179.60, with a volume of 2196788 shares trading hands. The stock had previously closed at $182.83.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on TWST shares. UBS Group began coverage on shares of Twist Bioscience in a research report on Wednesday, September 9th. They set a “neutral” rating and a $144.00 target price on the stock. TD Cowen reiterated a “buy” rating on shares of Twist Bioscience in a research report on Monday, August 3rd. Evercore cut shares of Twist Bioscience from an “outperform” rating to an “in-line” rating and set a $102.00 price target for the company. in a research note on Monday, July 6th. Canaccord Genuity Group raised their price objective on shares of Twist Bioscience from $90.00 to $120.00 and gave the stock a “buy” rating in a research report on Tuesday, July 14th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Twist Bioscience in a research note on Monday, September 21st. Eight research analysts have rated the stock with a Buy rating, two have given a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $105.73.

Twist Bioscience Stock Up 3.8%

The company has a market capitalization of $12.12 billion, a PE ratio of -87.04 and a beta of 2.22. The company has a current ratio of 2.67, a quick ratio of 2.38 and a debt-to-equity ratio of 0.03. The firm has a 50 day simple moving average of $132.52 and a two-hundred day simple moving average of $90.39.

Twist Bioscience (NASDAQ:TWST) last issued its quarterly earnings results on Monday, August 3rd. The company reported ($0.56) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.05). Twist Bioscience had a negative return on equity of 28.64% and a negative net margin of 31.66%.The company had revenue of $118.38 million for the quarter, compared to analyst estimates of $114.55 million. During the same period in the prior year, the business earned $0.33 earnings per share. Twist Bioscience’s revenue for the quarter was up 23.2% compared to the same quarter last year. Research analysts expect that Twist Bioscience Corporation will post -2.12 EPS for the current year.

Insiders Place Their Bets

In related news, insider Dennis Cho sold 412 shares of the firm’s stock in a transaction dated Tuesday, September 8th. The shares were sold at an average price of $122.62, for a total value of $50,519.44. Following the completion of the sale, the insider owned 73,651 shares in the company, valued at $9,031,085.62. This trade represents a 0.56% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Adam Laponis sold 2,399 shares of the company’s stock in a transaction dated Thursday, July 9th. The stock was sold at an average price of $94.33, for a total transaction of $226,297.67. Following the transaction, the chief financial officer owned 110,276 shares in the company, valued at $10,402,335.08. The trade was a 2.13% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders have sold 521,777 shares of company stock worth $78,416,543. Company insiders own 3.08% of the company’s stock.

Institutional Investors Weigh In On Twist Bioscience

Institutional investors have recently modified their holdings of the company. GAMMA Investing LLC increased its stake in Twist Bioscience by 24.4% in the 2nd quarter. GAMMA Investing LLC now owns 943 shares of the company’s stock valued at $97,000 after purchasing an additional 185 shares in the last quarter. Allworth Financial LP boosted its position in Twist Bioscience by 54.9% during the second quarter. Allworth Financial LP now owns 601 shares of the company’s stock worth $62,000 after purchasing an additional 213 shares in the last quarter. PNC Financial Services Group Inc. boosted its position in Twist Bioscience by 89.7% during the first quarter. PNC Financial Services Group Inc. now owns 958 shares of the company’s stock worth $46,000 after purchasing an additional 453 shares in the last quarter. Trifecta Capital Advisors LLC purchased a new stake in Twist Bioscience during the second quarter worth $63,000. Finally, Intech Investment Management LLC grew its holdings in Twist Bioscience by 2.6% in the fourth quarter. Intech Investment Management LLC now owns 25,477 shares of the company’s stock valued at $808,000 after purchasing an additional 643 shares during the last quarter.

Twist Bioscience Company Profile

Twist Bioscience Corporation (NASDAQ:TWST) is a biotechnology company that develops and manufactures synthetic DNA using a silicon-based production platform. Its technology is designed to enable the precise, high-throughput synthesis of DNA at smaller scale and with potentially lower material consumption than traditional methods.

The company provides synthetic DNA products and services for applications in drug discovery and development, biotechnology research, agriculture, industrial chemicals and other life sciences markets.